What is Nautilus Biotechnology, Inc. (NAUT) stock price today?

Nautilus Biotechnology, Inc. (NAUT) is currently trading at $2.37, up 29.95% today.

What is NAUT P/E ratio?

Nautilus Biotechnology, Inc.'s P/E ratio is -4.36. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NAUT return on equity (ROE)?

Nautilus Biotechnology, Inc.'s return on equity (ROE) is -37.58%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Nautilus Biotechnology, Inc.'s market cap?

Nautilus Biotechnology, Inc. has a market capitalization of $300.96M.

NASDAQ · Biotechnology

Nautilus Biotechnology, Inc. (NAUT) Stock

$2.37 +29.95% NASDAQ: NAUT Healthcare

Valuation

Metric	Value
Price	$2.37
Market Cap	$300.96M
P/E Ratio	-4.36
P/B Ratio	1.90
P/S Ratio	1312.74
EPS (TTM)	$-0.47
52-Week High	$4.31
52-Week Low	$0.82
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-37.58%
ROA	-34.55%
ROCE	-40.52%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.21
Current Ratio	13.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-50.0M	$-64.0M	$-76.0M	$-81.0M	$-67.0M
Net Profit	$-50.0M	$-58.0M	$-64.0M	$-71.0M	$-59.0M
EPS	$-0.60	$-0.46	$-0.51	$-0.56	$-0.47
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$398.0M	$350.0M	$306.0M	$243.0M	$191.0M
Total Liabilities	$35.0M	$35.0M	$40.0M	$34.0M	$34.0M
Cash	$186.0M	$115.0M	$19.0M	$28.0M	$12.0M
Borrowings	$30.0M	$30.0M	$35.0M	$30.0M	$30.0M

Latest News

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026 GlobeNewswire · Jul 8, 2026 3 Penny Stocks With Market Caps Over $100M To Watch Simply Wall St. · Jun 3, 2026 3 Promising Penny Stocks With Market Caps Up To $900M Simply Wall St. · May 5, 2026 Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans Simply Wall St. · May 5, 2026 Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... GuruFocus.com · Apr 29, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-39.0M	$-46.0M	$-52.0M	$-59.0M	$-51.0M
Investing Cash Flow	$-141.0M	$-28.0M	$-46.0M	$64.0M	$34.0M
Financing Cash Flow	$335.0M	$0	$0	$0	$0
Net Cash Flow	$149.0M	$-71.0M	$-95.0M	$8.0M	$-15.0M
Free Cash Flow	$-42.0M	$-48.0M	$-54.0M	$-61.0M	$-52.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.29
EV / EBITDA	-4.80
FCF Yield	-20.79%
Quick Ratio	10.14
Interest Coverage	0.00
Return 1Y	138.87%
Return 3Y	-44.86%
Return 5Y	-81.00%

Ownership

Insiders Held33.21%

Institutions Held40.78%

Institutions Float Held61.05%

Institutional Holder	Shares	Report Date
a16z Capital Management, L.L.C.	17,653,917	2026-03-31
Perceptive Advisors Llc	12,594,211	2026-03-31
Cercano Management Llc	7,172,985	2026-03-31
Vanguard Capital Management LLC	2,545,597	2026-03-31
Clearstead Advisors, LLC	2,329,784	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$337.01	-1.00%	38.93	$4.95T	0.32%
MSFTMicrosoft Corporation	$535.56	+2.48%	28.68	$3.98T	0.76%
GOOGLAlphabet Inc.	$351.83	+1.01%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.58	+3.35%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$719.34	-0.22%	27.93	$1.83T	0.28%

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is led by CEO Sujal Patel, employs 134 people, headquartered in US, publicly traded since 2020.

Nautilus Biotechnology, Inc. (NAUT) stock trades at $2.37 with a market capitalization of $300.96M. The stock is valued at a price-to-earnings (P/E) ratio of -4.36, price-to-book of 1.90, price-to-sales of 1312.74. Over the past 52 weeks the stock has ranged between $0.82 and $4.31, and currently trades 45.0% below its 52-week high.

On profitability, Nautilus Biotechnology, Inc. generates a return on equity (ROE) of -37.58%, return on capital employed of -40.52%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.52 +0.76% JNJ Johnson & Johnson $261.29 +1.88% ABBV AbbVie Inc. $276.40 +1.46% MRK Merck & Company, Inc. Common Stock (new) $145.57 +2.24% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.42 +2.28% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $657.76 +0.89% AMGN Amgen Inc. $414.83 +1.81% GILD Gilead Sciences, Inc. $151.22 +2.80% ABT Abbott Laboratories $99.71 +1.23% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides